Corcept Therapeutics (CORT) Misses Q1 EPS by 19c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $81.13 +0.01%
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.30), $0.19 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $183.28 million.
GUIDANCE:
Corcept Therapeutics sees FY2026 revenue of $0.95-1.05 billion, versus the consensus of $0.93 billion.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades Lumentum (LITE) to Strong Buy, 'Overreaction to Marvell Offer'
- Interactive Brokers reports October 2026 brokerage metrics
- H.C. Wainwright Defending Cipher Mining (CIFR)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
